However, alongside these generally complex evaluations, screening tools for anxiety and depression and QoL scores could be a practical and straightforward method to identify patients who are likely to remain symptomatic after CRP and who may benefit from specific MH interventions. This evidence concerns the gene CRP and depressive disorder.